Nanosecond Pulsed Electric Field (nsPEF) Ablation as an Alternative or Adjunct to Surgery for Treatment of Cancer

Ru Chen1,2, Xinhua Chen1,3 and Stephen J Beebe1*

1Frank Reidy Research Center for Bioelectrics, Old Dominion University, VA 23508 USA
2Ethicon Endo Surgery, Cincinnati Ohio, USA
3Department of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Zhejiang University School of Medicine, China

Abstract

Surgery as resection or transplantation remains a fundamental means for cancer treatment and often offers an opportunity for a cure. However, surgery is not always possible because of tumor proximity to blood vessels or ducts or when a patient is not healthy enough to undergo surgery. Application of nanosecond pulsed electric fields (nsPEFs) is a new approach to treat cancer using pulse power technology that was originally designed for military purposes. This novel approach deposits extremely short pulses of high power, low energy electric fields into malignant tissues using electrodes to encompass tumors. Pre-clinical studies show that treatments are effective and without local or systemic side effects, including absences of scarring. Pre-clinical trials for basal cell carcinoma are completed, but results have not been published. For treating internal tumors, electric fields can be delivered by catheter electrodes and laparoscopy procedures. Here we present a review of the literature using nsPEFs for cancer ablation and present some recent work from the author’s laboratory. We demonstrate efficacy for treatment of an ectopic mouse (Hepa-1-6) and an orthotopic rat (N1-S1) Hepatocellular Carcinoma (HCC). NsPEFs eliminate tumors by mechanisms in the presence of active caspases (apoptosis) as well as in absences of active caspases (necrosis/necroptosis). Treatment also breaches small vessels, but spares larger vessels and ducts. NsPEF treatments also reduce angiogenesis as determined by decreases in Vascular Endothelia Growth Factor (VEGF). Microvascular density markers (CD-31, CD-34 and CD-105) are significantly decreased after treatment, limiting new blood vessel formation and reinforcing tumor cell demise. Furthermore, initial challenge studies show that mice are resistant to re-introduction of the same tumor cells after treatment, suggesting that nsPEFs induces immunogenic cell death and possible host cell immune responses after treatment. NsPEF ablation of cancer targets at least three hallmarks of cancer (evasion of apoptosis, angiogenesis maintenance and immune surveillance) and provides an effective alternative or adjunct therapy for cancers in skin and internal organs.

Keywords: Pulse power; Fibrosarcoma, Melanoma; Hepatocellular carcinoma; Basal cell carcinoma; Pancreatic cancer; Cancer hallmarks; Apoptosis; Caspases; Microvascular density markers

Introduction

Brief highlights in the history of surgery

Perhaps the earliest evidence of surgery came from burial sites in France (6,500 BC) where indications of trepanation or drilling a hole in the skull were found [1]. These surgeons were nameless, but Urgalgedin (4,000 BC) was known as a surgeon in a cradle of civilization in the Tigris - Euphrates river valley in Mesopotamia [2]. Other early noteworthy surgeons included Imhotep (circa 2650–2600 BC), an Egyptian scholar who was perhaps the first physician in early history and was considered the Egyptian god of medicine [3] and the god of science and thought [4]. He authored a medical treatise that excluded magic from medicine and contained anatomical observations, ailments, treatments and cures [5]. Sushruta (1000-600 BC), who was known as the "father of surgery", practiced in Northern India around 600 BC [2]. He authored the oldest known text in surgery, which included details of examinations, diagnoses, treatments, and prognoses of numerous ailments in addition to procedures on cosmetic surgery, plastic surgery and rhinoplasty [6]. The ancient Greeks, Herophilos and Erasistratus (~300 BC), were the first scientists to systematically dissect human cadavers. They founded the School of Anatomy in Alexandria from which came descriptions of ligature (hemostasis), lithotomy, hernia operations, ophthalmic surgery, plastic surgery, methods of reduction of dislocations and fractures, tracheotomy, and mandrake as anesthesia [7,8]. Hua Tuo (c. 140–208) [9], an ancient Chinese physician, was the first person to perform surgery with the aid of anesthesia (mafeisan or "cannabis boil powder") about 1600 years before Europeans. Hippocrates, the "father of western medicine" founded the Hippocratic School of Medicine, which revolutionized medicine by establishing it as a distinct discipline and profession [10]. He spent 20 years in prison for differentiating medicine from religious beliefs, arguing that disease resulted from environmental factors, diet and living habits instead of punishment from gods [11]. Galen (c. 129-200) [12], another Greek, who lived in the Roman era, was a very accomplished surgeon and physician who carried out very complex surgical operations and added significantly to our understanding of surgery as well as animal and human physiology. Throughout history, surgery made regular advances in times of war. Modern surgery did not begin until three major problems were resolved. These were pain, bleeding and sepsis. Anesthetics such as ether (1500s), nitrous oxide (early 1800s) and ether-chloroform (1840s) contributed significantly to the pain problem. Louis Pasteur (1822-1895) advanced the idea that bacteria caused infections; however, this idea was slow to be accepted. Lister (1827-1912) controlled infection using antiseptic surgery. This was followed by sterilization, use of rubber gloves and antibiotics, all contributing to the problem of infections. Before the bleeding problem could be settled, physicians had to realize that loss of blood was a major problem for survival. Bleeding patients was common practice for almost every ailment for hundreds of years. When physicians finally

*Corresponding author: Stephen J Beebe, Frank Reidy Research Center for Bioelectrics, Old Dominion University, VA 23508, USA, Tel: 757-683-2405; Fax: 757-451-1010; E-mail: sbeebe@odu.edu

Received March 07, 2013; Accepted March 30, 2013; Published April 10, 2013


Copyright: © 2013 Chen R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
realized hemostasis was critical for survival, bleeding was controlled by point pressure, tourniquets, cauterizations and ligatures. Replacing lost blood was addressed by transfusions, but understanding concepts of blood groups was required before transfusions were successful. There are a number of claims to the first “modern” surgery. Pertinent to this review, the Mayo brothers and father, who founded the Mayo Clinic (1914), conducted one of the first surgeries in the US by removing a cancerous growth from a patient at St. Mary’s Hospital (1905). Other significant advance is surgery came with the first successful kidney transplant (1954) at Peter Bent Brigham Hospital in Boston, MA [13] and the first successful heart transplant (1967) at Cape Town South Africa [14]. Other highlights in chronicles of surgery include the invention of the fiber optic endoscope (1963-64), laparoscopic or minimally invasive surgery and more recently, robotic surgery, including one or the earliest placing a needle for a brain biopsy (1985) [15] and prostate surgery (1988) [16]. Today robotics can be used in essentially all aspects of general surgery.

Materials and Methods

Alternative therapies for treatment of cancer

At the other end of these developments is the replacement of surgery or inclusion of other treatments as adjuncts to surgery for treatment of cancers. For the purposes here, an overview of the earliest examples of nsPEF treatment of cancer and then a focus on Hepato Cellular Carcinoma (HCC) with an ectopic mouse model and an orthotopic rat model. For treatment of HCC, there are a number of alternative treatments to surgery with several relatively new technologies [17,18] using thermal approaches [radiofrequencies (RFA), microwaves (MWA), cryoablation] chemical-techniques (percutaneous ethanol/acetate acid), radiological methods (transarterial chemoembolization and radioembolization, also RFA), High Frequency Ultrasound (HIFU) treatment. Importantly, there have been a number of non-thermal methods used as alternatives to surgery and many of them use local electric fields as a means of treatment. More than a quarter of a century ago, it was shown that non-thermal applications of electric fields could alter plasma membranes of cells to transport DNA across their membranes. The authors proposed that electric field interaction with lipid dipoles at local defects in the plasma membrane could cause disordered structures, leading to permeation sites for DNA entry [19].

Electro gene therapy, or gene delivery to cells or tissues, is now being used in clinical trials and has been shown to be clinically safe and effective for deliveryIL-12 to melanoma patients [20]. Another non-thermal use of electric fields came into practice in a similar way to that used for gene transfer. Instead, electroporation was used to deliver chemotherapeutic drugs such as bleomycin that were impermeable to plasma membranes [21]. This is now commonly practiced in Europe for treatment of cancer [22]. Another non-thermal approach for treating cancer is to increase electric fields such that electroporation is irreversible, thereby eliminating tumor cells by Irreversible Electroporation (IRE) of plasma membranes [23,24]. At about the same time, nanosecond pulsed electric field (nsPEF) ablation was being explored in vitro and in vivo and is the major interest in this review.

Nanosecond pulsed electric field (nsPEF) ablation as a cancer treatment

Applications of nsPEFs have been used to eliminate several tumor cell types in vitro and tumor tissues in vivo. This approach uses pulse power technology that was originally designed for military applications. It stores intense levels of electric energy and then unleashes nanosecond bursts of instantaneous power into cells or tissues. This is believed to be significant because it creates unique intracellular conditions of high power and low energy. Because the pulses are so short, when using low pulse repetition rates, the method is essentially non-thermal [25,26]. However, when repetition rates are higher, some heat is generated. However, if temperatures do not increase to more than 40-42°C, the treatment can still be considered non-thermal. For example, in the first study treating B16f10 melanoma tumor in vivo, the temperature in the treated tumor rose from 28° to 31°C, clearly non-thermal [26]. In addition, ablation zones are very clearly defined based on electrode placements [27]. This allows precise treatment of tumors with appropriate margins of adjacent tissue, thereby minimizing damage to non-tumor tissue. Although there is some cell type specificity with nsPEFs [28,29], all cells surrounded by electrodes and exposed to sufficiently high electric fields should be affected and undergo cell death. Not only will cancer cells be affected, but other cells will be affected including host cells that support tumor growth and slow growing cancer stem cells that are not affected by agents that target rapidly proliferating cell, will be affected. nsPEF ablation induces caspase-dependent and caspase-independent programmed cell death [30], at least in part, by inducing supra-electroporation [31,32], which consists of high density nanopores, not only in plasma membranes but also in organelle membranes and possibly other mechanisms such as effects on voltage gated channels [33] and perhaps on proteins [34,35]. The effect on intracellular membranes is significant because permeabilization of plasma membranes is not always sufficient for cell death induction under nsPEF conditions [35]. While poration of plasma membranes and intracellular stores is critical for elevating intracellular calcium, effects on mitochondria membranes and/or channels and the mitochondria membrane potential (ΔΨm) appear to be required for nsPEF-induced cell death, at least under certain conditions [35]. Thus, by targeting plasma membranes, ΔΨm, and/or membranes surrounding intracellular calcium stores, applications of nsPEFs affect multiple therapeutic targets and cancer hallmarks [36].

Treating ectopic mouse B10.2 fibrosarcomatums with nsPEFs

The first application of nsPEFs for cancer treatment was using B10.2 fibrosarcoma cells in vitro and in a mouse tumor xenograft model [37]. One of the major points was showing that nsPEFs differed from conventional electroporation. In so doing, in vitro studies exposing cells to nsPEFs in cuvettes demonstrated that nsPEFs induced apoptosis markers including the presence of active caspases and phosphatidylserine externalization, which was most likely due to direct electric field effects on plasma membranes [38]. In tissues removed from ectopic tumors and treated ex vivo in cuvettes, a 6-fold increase in TUNEL positive cells was observed compared to sham treated controls 5 hours after treatment with nsPEFs. Mouse B10.2 tumors were also treated in vivo. These treatments primarily served as a proof of principle that nsPEFs could have a deleterious effect on tumors. Tumor cells were implanted in each flank of mice. One tumor served as a sham control and the contra lateral tumor was treated. Since these were the first in vivo studies carried out with nsPEFs, there were no guidelines to choose treatment conditions. After tumors reached about 5-8 mm in diameter as measured by calipers (day 0), tumors were exposed to two pulses with durations of 300 ns and electric fields at 75 kV/cm and 1 Hz on day 2 and 5 pulses under the same conditions on day 5using a two needle electrode. In 5 animals, treated tumors grew 62% slower than sham controls. In three other animals, treated tumors were 60% smaller by weight than sham controls. It is now known that these treatment conditions were far less rigorous than needed for tumor elimination based on results from treatment of ectopic mouse B16f10
Treating mouse B16f10 melanoma tumors in vivo with nsPEFs

Later, nsPEFs were shown to eliminate mouse B16f10 tumor in a mouse ectopic model without recurrence under optimal conditions [26]. In these studies two different delivery electrode designs were tested including a 5 needle array and two parallel plates. When the 5 needle array was used, the electric fields were heterogeneous with the highest field at the center needle and field lines parallel to the surface of the skin. Treated tumors shrink by about 75% within 8 days when given two treatments with 100 pulses with durations of 300 ns and electric fields at 20 kV/cm and 0.5 Hz. Tumor responses were dependent on electric fields and pulse numbers. After pulsing, blood flow to tumors was interrupted and did not recover for about two weeks.

In addition to tumor damage, the stratum corneum was damaged, showing signs of necrosis and hemorrhage. Interestingly, this was not a thermal injury or a burn, which would be expressed immediately; the temperature increase was only 3°C, significantly lower than required for a hyperthermic injury. Thus, this is more likely an electrical injury, perhaps due to effects on proteins caused by dissociation of ionizable side groups, reorientation of peptide dipoles within the protein in the direction of the electric field, conformational changes and denaturation [40]. Using the plate electrode design, tumors were positioned between parallel plates. This provided a more homogeneous electric field, which was oriented perpendicular to the skin surface instead of parallel to it, like that with needle electrodes. In this configuration, the surface of the skin was between electrodes and the tumor. Using four 100 pulse treatments (3 on day 0 and 1 on day 3) and electric fields of 40 kV/cm, tumors shrank by 90% in two weeks. The skin responded with a black scab on the stratum corneum, composed of clotted red blood cells, which remained for about two weeks during regeneration of the stratum corneum. After about two weeks of regression, all tumors began to grow again.

When tumors began to grow again and were given additional treatments including a 3 day series of 100 pulses, a complete remission was observed for as long as two months. Two immediate changes after nsPEF treatment were hypothesized to cause tumor regression. One was a rapid pyknosis of tumor nuclei and the other a cessation of blood flow to tumors. Within the first few minutes, tumor cell nuclei shrank by 54% and within 3 hours they shrank by 68%. The absence of blood flow to tumors within the first 15 minutes after treatment was indicated by trans-illumination and power Doppler ultrasound reconstructions. As long as blood flow did not return to treatment areas, tumors did not return; however, if blood flow returned with two weeks after treatment, tumor growth returned. In addition to killing tumor cells, as indicated by pyknotic tumor cell nuclei, the absence of blood flow appears to be an important factor to tumor regression. In later studies, it was shown that B16f10-eGFP tumors could be eliminated in a single treatment using 2000 pulse with duration of 100 ns at 30 kV/cm at 5-7 Hz [41]. These studies differ from the previous one in several ways. This study used Nu/Nu mice, which are immunodeficient, instead of SKH-1 mice, which have a relative strong immune system. The treatments were with shorter pulse durations (100 ns instead of 300 ns) and higher repetition rates (5-7 Hz instead of 0.5 Hz). The higher repetition rate caused temperatures to increase to about 40°C, yet the treatment was still considered non-thermal. Another difference included using suction electrodes, which were compatible for human use. This design limited the treatment volume to tissues that could be placed between electrodes within the suction cup. The skin was also affected by this nsPEF treatment; however, scabs that formed fell off by the end of the second week, leaving a coloration difference from untreated skin that faded leaving no scar. In unpublished clinical trials, nsPEFs affected human skin causing only mild irritation, erythema and itching leaving some discoloration that faded and no scar [42]. Thus, an important advantage and benefit for nsPEF treatment of skin cancer over surgery is the absence of scarring after treatment. Effective ablation was achieved in radiation-induced murine Basal Cell Carcinomas (BCC), which was similar to human BCC, in Pten+/- K14-Cre-ERp53fl/fl mice using a 6-post dual configuration suction electrode, which was the best of three electrode designs tested. The electrode configuration and complete encapsulation of the tumors were critical components for complete ablation in a single treatment. Using 2700 pulses with 100 ns durations and electric fields of 30 kV/cm at 5-7 Hz, BCC tumors shrank 76% at 2 weeks and 99.9% at four weeks after treatment [43]. Complete ablation without recurrence of human pancreatic carcinoma was also demonstrated in a murine xenograft model using similar conditions, but with 500-1000 pulses showing good efficacy [44].

The devastation of Hepatocellular Carcinoma

Liver cancer is the third most common cause of mortality worldwide [WHO statistics] and Hepato Cellular Carcinoma (HCC) is the most common, occurring in 75% of all liver cancers [45]. Africa and Southeast Asia have highest incidences of HCC and it is the most common cancer in Japan. The incidence and mortality rates of HCC are nearly equal because the fatality rates are so high. The prognosis for HCC is usually poor because symptoms and diagnosis do not generally occur until advanced stages. The incidence and mortality rates have increased recently in the US and are affecting younger persons, mostly due to increased infections with hepatitis C and B viruses [46]. While the prognosis of cancer patients is generally determined by tumor size, HCC treatment efficacy is also determined by underlying diseases such as cirrhosis or other functional maladies [47]. These underlying diseases, in part, account for poor responses to chemotherapeutic agents and ionizing radiation and also account for <20% of patient eligibility for resection. Still, several new developments have led to increases in early diagnoses including greater awareness of the disease, new screening approaches and more definitive diagnosis using high-resolution imaging of the liver [48]. Yet, a major remaining barrier is the absence of successful management strategies that avoid multiple treatments and prevent recurrences. One of the most comprehensive classification system used for HCC in the US is the Barcelona-Clinic Liver Cancer (BCLC) staging classification and treatment schedule [49,50]. The system includes 5 tumor staging categories that consider size and number of nodules, the degree of liver function and the presence or absence of metastasis. They include very early (0), early (A), intermediate (B), advanced (C) and terminal (D) stages. Stages O, A and B are treated with resection, liver transplantation, percutaneous ethanol (or acetic acid), radiofrequency ablation or Transcatheter Arterial Chemoembolization (TACE). Advanced and terminal stages are generally treated with palliative measures. HCCs are generally resistant to chemotherapeutic agents and radiation. For example, sorafenib is a new oral multi-kinase inhibitor for advanced HCC with modest clinical efficacy extending survival by only a few months [51,52]. New treatment strategies are needed for stages O, A and B.
that avoid multiple procedures and recurrences. This is a niche that can be filled using pulse power technology with nanosecond pulsed electric field (nsPEF) ablation of HCCs. Hepatocytes are the major liver cell type and are vulnerable to most forms of liver injury either as primary or secondary insults. Continuous cell turnover by apoptosis, which is tightly coupled to inflammation and fibrosis [53-55], leads to activation of myofibroblasts, hepatic fibrosis, cirrhosis and HCC [56]. Such chronic pro-apoptotic pressure provides the basis for cancer-related mutations and promotes development of apoptosis evasion [57], a hallmark of cancer [36]. Production of pro-inflammatory products from macrophages, stellate cells and Kupffer cells during phagocytosis of apoptotic bodies appears to be responsible for the link between apoptosis and fibrosis [53,57,58], a paradigm that appears to be unique to hepatocyte apoptosis. Cancer also emerges when immunological control fails and transformed cells develop resistance against cell death signaling pathways. The same mechanisms underlie the poor responsiveness of HCC towards chemotherapy. Mechanisms of cell death exhibit complexity beyond apoptosis and necrosis as cross-talk among signaling pathways involved in cancer hallmarks makes clear. Also the tumor microenvironment has an impact on cell signaling and cell death. While significant progress has been made in understanding tumorigenesis and cancer molecular biology, the overall therapeutic effects on cancer mortality have been disappointing. While the primary pathways that drive cancer are known and a significant number of drugs targeted for these pathways have been developed and tested, virtually none of these drugs or treatments has provided a cure. The scientific community is conceptually reexamining approaches for cancer treatment, considering cancer as manifestations of eight essential hallmarks [36] and instead of conceiving cancer as a foreign invader [59], reevaluating cancer as a criminal gang (the cancer) within the local community (cancer microenvironment) that coerces the local population (supporting host cells, blood vessels) to use their resources (growth, differentiation and vessel-forming factors) to support the gang’s criminal activity (the tumor as an organ).

**Treating ectopic mouse Hep1-6 HCC tumors in vivo with nsPEFs**

As a first step to address the possibility of using nsPEFs for treating HCC, an ectopic mouse Hep1-6 HCC tumor model was established in C57BL/6 mice and optimal conditions were determined as well as cell death mechanisms in response to nsPEF [60]. In this study a number of different conditions were tested. Pulses with durations of 30 or 100 ns and fast rise times were delivered by an electrode with a5 needle, 4 + 1 configuration or an electrode with a center needle and a solid ring surrounding it. The electric field distribution in both electrode configurations were heterogeneous with electric fields as high a 230 kV/cm at the center needle with electric fields decreasing towards the ground electrodes, where electric fields were on the order of 40-90 kV/cm [60]. Different electric field strengths (33, 50 and 68 kV/cm) were tested with 900 pulses delivered at 1 Hz as a single treatment or as 3 separate treatments on days 1, 3 and 5 with 300 pulses each. The mice were followed for 269 days after treatment. For those mice that survived after treatment, this is a significant cancer free span considering this is approximately half of a mouse’s life expectancy. If this would translate to humans with an average life expectancy of 80 years and ignoring differences in cancer growth rates, which varies significantly among cancers, an individual who was diagnosed with cancer and successfully treated by the age of 40 could live cancer free of the rest of their life. This is significant since with optimal treatment conditions, 75% of treated animals survived this long when the experiment was terminated. In these studies, optimal treatments with 75% survival include 900 pulses either delivered at one time or 3 times with 300 pulses each on alternate days, with durations of 100 ns and electric fields at 65 kV/cm and 1 Hz. Generally, after tumors were treated, they stabilized or grew slightly larger until the third day when they decreased in size and were non-detectable by 14-21 days. Control, sham treated tumors continued to grow for about 14-18 days when mice were humanely euthanized due to tumor burden. When pulse durations were decreased to 30 ns or electric fields were decreased to 33 or 50 kV/cm, treatment efficacies were significantly lower. For those tumors that were treated under optimal conditions, the tumor cell nuclei rapidly decreased in size during the first hour. Tumor cell nuclei featured highly condensed chromatin, segregating into sharply defined bodies (nuclear pyknosis) by 3-6 hours after treatment. Fifty to sixty percent of treated tumor nuclei were TUNEL positive by 3 hours after treatment. The number of TUNEL positive cells decreased thereafter over the next 12-24 hours. The presence of active executioner caspases, as identified by specific antibodies, followed a similar time course after treatment. The presence of active caspase-3, -6 and -7 peaked at 3 hours and decreased thereafter over the next 5 hours. Active caspase-3, -6 and -7 activity was present in about 45-50%, 12-18% and 20-40% of cells, respectively, 3 hours after treatment at their peak. Activities of caspase-3 and -6 fell off rapidly between 4-8 hours after treatment but caspase-7 activity fell at a slower rate. Since these analyses were carried our separately, it is not possible to know whether a given cell exhibited more than one or more than one active caspase or whether there were cell type specificity for specific caspases. Nevertheless, it is likely that not all cells exhibit active caspases and are undergoing caspase-independent cell death. Since after efficacious treatment all tumors disappear, there are few or no cells that do not undergo cell death. Another indicator of apoptosis was the absence of phosphorylated Bad in effectively treated Hep1-6 tumors. When Bad is phosphorylated, it is bound to the protein 14-3-3, which removes it from possible heterodimerization with Bcl-xL or Bcl-2, which neutralizes their protective effect on mitochondria thereby promoting survival [61]. When Bad is in the un-phosphorylated form, which was present in treated Hep1-6 tumor cells, it heterodimerizes with Bcl-xL or Bcl-2, thereby removing their protective effect promoting cell death. Therefore, the presence of active caspases and the absence of phosphorylated Bad are conditions that promote cell death by apoptosis. It was previously shown that nsPEFs had significant effects on tumor vascularity in B16f10 melanoma tumors in vivo [62]. In these studies, it was shown that there were progressive decreases during 21 days after treatment in Vascular Endothelial Cell Factor (VEGF), the most ubiquitous pro-angiogenic factor, a requirement for the angiogenic switch [63], a limiting factor for multistage carcinogenesis [36] and Platelet Derived Endothelial Growth Factor (PD-ECGF). In addition there were progressive decreases over this same time period for several micro vascular density factors, including CD-31, CD-34 and CD-105. CD-31 (PECAM-1), a platelet-endothelial cell adhesion molecule used as a pan-endothelial cell marker, and CD-34, an endothelial cell marker, were decreased by 65-70%. CD-105 (endoglin) was decreased >40%. CD-105, which is part of the TGFβ receptor complex, is an important angiogenic factor that is strongly expressed in tumors and is an independent prognostic indicator, wherein increased MVD correlates with shorter survival [64].

**Does nsPEF treatment induce an immune response in ectopic mouse Hep1-6 HCC tumors?**

Using this same mouse Hep1-6 model in C57BL6 mice, we decided to challenge mice with a second injection in the opposite flank of the same Hep1-6 tumors cells after the primary tumor had been successfully cleared for 60 days [65]. Age match, naive control mice were also
Treated orthotopic rat N1-S1 HCC tumors in vivo with nsPEFs

In more recent studies, we have established and tested an orthotopic rat N1-S1 HCC using conditions similar to those in the Hep-1-6 mouse model discussed above. The studies carried out previously demonstrated that nsPEF could effectively eliminate tumors when they were implanted under the skin. We wanted to extend applications of nsPEFs to treating internal tumors. Given successes with the ectopic mouse HCC model and the "HCC problem", which is increasing in the US and already a major problem worldwide, we pursued application of nsPEF to HCC tumors implanted in the liver of rats. We chose a rat model because of the larger liver and the need to carry out two surgeries and later three surgeries to demonstrate efficacy of nsPEFs. Thus, these studies combine nsPEF treatment with laparotomy as a proof or principle, before establishing treatments with laparoscopy and catheter electrodes. Thus, in this model, we introduced N1-S1-Luc cells under the liver capsule through a small incision in the abdominal wall. N1-S1 cells were stably transfected with a luciferase gene downstream of a CMV promoter. When tumors grew to about 0.5 cm, we exposed the liver again and treated with nsPEFs before closing. Tumor growth was monitored by luciferase activity (luminescence) ultrasound. In this model, we used a 5 needle (4+1) array [60] and treated tumors using nsPEF treatment with laparotomy as a proof or principle, before establishing treatments with laparoscopy and catheter electrodes. Thus, in this model, we introduced N1-S1-Luc cells under the liver capsule through a small incision in the abdominal wall. N1-S1 cells were stably transfected with a luciferase gene downstream of a CMV promoter. When tumors grew to about 0.5 cm, we exposed the liver again and treated with nsPEFs before closing. Tumor growth was monitored by luciferase activity (luminescence) ultrasound. In this model, we used a 5 needle (4+1) array [60] and treated tumors using nsPEFs.

Analysis of HCC tumors by size and bioluminescence after nsPEF treatment

Figure 1 shows results indicating tumor sizes were decreased with all pulse numbers. Using 100 pulses tumor sizes were decreased but were only significantly less than sham-treated controls 14 days after treatment. Tumor sizes were smaller using 300, 500 and 1000 pulses with the later condition decreasing tumor size about 6-fold. In subsequent experiments, when treated tumors were measured 6 weeks later, the 100 and 300 pulse conditions were insufficient to eliminate tumors; tumors had continued growing slowly between 2 and 6 weeks after treatment. We had initiated tumor development using an N1-S1 clone stably transfected with luciferase to monitor tumor growth by luminescence. Figure 2 and table 1 shows tumor luminescent images of the same rats taken in the IVIS 100 in a sham-treated control and a rat treated with 1000 pulses with durations of 100 ns and electric fields at 50 kV/cm delivered at 1 Hz. Luminescent images were determined on the day of treatment (day 0) and 7 and 10 days after treatment. The image below shows luminescent images and tumor sizes based on luminescence. Tumors from one sham-treated and one typical nsPEF-treated rat are shown as examples. It can be seen that by day 7 the sham treated tumor grew 5-6-fold compared to the size just before treatment and continued to grow for 10 days. In the treated rat, there was no detectable luminescence, indicating that treated tumors were absent 7-10 days after treatment. In order to evaluate longer term efficacy of nsPEFs, we treated tumors and evaluated the presence or absence of tumors seven weeks post-treatment. Figure 3 shows a Kaplan-Meier survival curve [67] for one experimental series with 7 rats that were sham treated and 8 rats that were treated with 1000 pulses with durations of 100 ns and electric fields at 50 kV/cm and 1
Figure 2: NsPEFs eliminate N1-S1-Luc tumors determined by luminescence 7-10 days after treatment. - Tumors were initiated as indicated in the legend to Figure 1. Seven days after initiation tumors were treated with 1000 pulses (1000X) with durations of 100 ns and electric fields at 50 kV/cm at 1 Hz. On the day of treatment (day 0) and 7 and 10 days after treatment, tumor bioluminescence was determined on the same animals using non-invasive in vivo imaging with the IVIS Spectrum (Caliper Life Sciences, Xenogen). One sham-treated tumor and one typical rat with a treated tumor are shown.

Table 1: The table below indicates the luminescence units and tumor area in cm². The designation 1000X indicates that tumors were pulsed 1000 times.

<table>
<thead>
<tr>
<th>Days post-treatment</th>
<th>0 days</th>
<th>7 days</th>
<th>10 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>9.47×10⁶</td>
<td>5.40×10⁵</td>
<td>2.8×10⁴</td>
</tr>
<tr>
<td>1000X nSPEFs</td>
<td>1.54×10⁷</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Effect of nsPEF treatment on liver blood flow

It was previously demonstrated that nsPEFs had significant effects on blood flow in the areas of treated ectopic B16F10 [26,62] and Hepa-1-6 HCC tumors [60]. While this was advantageous to inhibit ectopic tumor growth, we were interested to evaluate post-treatment liver blood flow, which is heavily vascularized. Effects on liver blood flow are important in HCC treatment since it is common for HCC patients to have compromised liver function. Figure 4 shows blood flow analysis by laser Doppler before, immediately after and 7 days after treatment. Immediately after treatment, blood flow was decreased by 50-60% in the treated liver area. Only the treated area was affected. However, 7 days later, blood flow had returned to normal and tended to be greater than the original control. This suggests that in nsPEF treated liver, effects on blood flow or anti-vascular effects or effects on angiogenesis, which occurred in ectopic tumors, is not likely to be a factor or a cancer hallmark in nsPEF treated HCC demise. Nevertheless, nsPEF treatments are an effective therapy for HCC.

Histological examination of normal liver and sham and HCC treated tissue

In order to determine effects of nsPEFs on treated N1-S1 HCC tumor tissue and compare it to normal liver and sham-treated control tumor tissue, we collected samples two weeks post-treatment from each of these tissues and prepared them for H&E staining and microscopy (Figure 5). The image of normal control liver shows a central vein and normal lobular hepatic architecture with cellular cords radiating from it with asymmetrical sinusoids and a typical scattering of collagen. In sham treated N1-S1, cancer cells can be seen infiltrating normal hepatic tissue with globular-like structures and sparse nuclei. Leukocyte infiltration in peripheral areas is evident. The vascular structures containing red cells are irregular and more numerous than in normal liver. In nsPEF-treated N1-S1 HCC, the cancerous tissues is completely destroyed with an absence of globular cancer cells and an enormous infiltration of leukocytes. We more-or-less expected this massive leukocyte infiltration given our previous results in Hepa-1-6 HCC treated tumors. We had previously observed that after successfully treating Hepa-1-6 HCC mouse tumors with nsPEFs (1000 pulses, 100 Hz. The results show that the all sham-treated rats had to be humanely euthanized by 25 days after tumor initiation because of tumor burden (1.5-2.0 cm) according to our IACUC protocol. All 8 rats treated with nsPEFs remained alive and tumor-free for at least 49 days. When tumor size was checked after humane euthanasia or when rats were exposed to a second challenge injection of N1-S1 tumor cells, treated tumors were complete absent and liver tissue had returned to normal hepatic structure in the treated area.

Figure 3: NsPEFs eliminate tumors for as long as 7 weeks. – N1-S1-Luc tumors were initiated and treated with 1000 pulses with 100 ns durations and 50 kV/cm at 1 Hz. In this typical trial, 7 sham and 8 treated rats were treated. After treatment, tumors were followed and analyzed by ultrasound. When sham treated tumors reach 1.5 cm, they were humanely euthanized according to our IACUC approved protocol. Forty nine days after treatment the experiment was terminated and animals were humanely euthanized. All surviving animals had been treated and were tumor free. The designation 1000X indicates that tumors were pulsed 1000 times.

Figure 4: Blood flow to the treated tumor area is transiently reduced. - N1-S1-Luc tumors were initiated and treated as describe in the legend to Figure 1. Before, immediately after and 7 days after treatment, Liver blood flow in the treated area was determined by laser Doppler imaging (Moor LDLS laser Doppler imager) and expressed as perfusion units. The data are expressed as percent of blood flow immediately before treatment. The * indicates the change is significant compared with pre-treatment (one way-ANOVA, p<0.01); # indicates the two post-treatment groups are statistically different (two way-ANOVA, p<0.001). The designation 1000X indicates that tumors were pulsed 1000 times.
late apoptotic or secondary necrotic secretion of high mobility group box 1 (HMGB1), which acts on the toll-like receptor-4 on dendritic cells, stimulates optimal antigen processing [68,72]. It will be interesting to determine whether nsPEFs exhibit some of the characteristics of immunogenic cell death. Such responses would provide significant advantage to prevent tumor recurrence and possibly vaccinate against HCC tumors that express the same antigen(s).

NsPEFs combined with other treatment modalities

NsPEF ablation impacts several well-characterized cancer therapeutic targets. It has shown success as a substitute for drug therapy and can be used in combination with other treatments; multiple therapies are common in essentially all cancer treatments and have been tried with nsPEFs [73]. In studies using concurrent treatments with low concentrations of gemcitabine and nsPEFs in mouse Cal 27 squamous cell carcinoma cells, synergistic activities were observed compared to summation of both treatment alone for inhibiting cell proliferation and inducing apoptosis and necrosis. The synergistic response was non-specific, or at least not universal, since no synergism for cell invasion was observed with combined treatments. While these experiments were designed to reduce tumor burden with nsPEFs before chemotherapy, other strategies could include sensitizing tumors with a chemotherapeutic agent(s) before treating with nsPEFs or reducing tumor burden with nsPEFs before resection.

Summary of cancer treatment with nsPEFs

NsPEF ablation therapy has a number of advantages for anti-tumor effects. They have several therapeutic targets, which are included in a single treatment as opposed to treating cancer with individual agents that affect evasion of apoptosis, sustained angiogenesis (or anti-vascular), and evasion of immune responses. The anti-vascular effect may be limited to tumors implanted or developed in the skin; however, additional studies of vascular effects in highly perfused liver warrant further investigation. The evasion of immune responses assumes the latter response is supported by further testing with nsPEFs in vivo. Certainly this last response will provide a substantial benefit for cancer treatment. Furthermore, nsPEFs induce cell death by caspase-dependent and –independent mechanisms [30] by targeting mitochondria and plasma membranes for calcium influx [35]. The heterogeneity of these effects is meaningful because nsPEFs can bypass a number of possible cancer mutations when tumor cells are adequately treated as shown here for treating N1-S1 HCC. For example, since nsPEFs can induce caspase-independent cell death, oncogenic mechanisms that evade apoptosis can be superseded. In contrast, the treatment itself is well defined by placement of electrodes to surround the tumor [27]. This stipulates specificity for tumor tissue and surrounding margins to minimize damage to surrounding non-cancerous tissues. When electric fields are sufficiently intense within this treatment zone, all cells can be killed, including tumor cells and host cells that provide needed growth and angiogenic factors for tumor growth, sustenance and metastasis. Given that nsPEFs can eliminate cells regardless of their proliferation rate, and in fact require less intense conditions (fewer pulses or lower electric fields) for cells that are not proliferating (are not in the S-phase) [74], it is likely that when electric fields are high enough, nsPEFs can also eliminate slowly dividing cancer stem cells, which could eliminate one possible cause of recurrences of disease, which can occur with agents that only affect rapidly proliferating cells. For treatment of skin tumors, nsPEF do not appear to leave scars after treatment in mice [26] or humans [42]. This will have valuable significance for individuals with skin cancer. Finally, there is an absence of local or systemic side effects with nsPEF treatment, providing an improvement over treatment with chemotherapeutic agents and ionizing radiation. When

Does nsPEF treatment induce an immune response in orthotopic rat N1-S1 HCC tumors?

In ongoing studies, rats with successfully treated tumors have been challenged with a second injection or a challenge injection of the same N1-S1 cells that initiated original tumors. In these preliminary studies the challenged tumors do not grow while naive age-matched control rats grow tumors like those tumors in sham treated control rats. This suggests that, like response to challenge in ectopic Hepa1-6 in mice, response are similar in rats, indicating that this phenomena is not species specific, is evident in an orthotopic HCC model and not confined to tumors originating in skin. The absence of challenge-tumor cell growth after successful nsPEF treatment of mouse Hepa1-6 and rat N1-S1 HCC tumors suggests the presence of immunogenic cell death. These results also indicate that these nsPEF-induced challenge phenomena are not species-specific. The mechanisms for immunogenic cell death are becoming clearer; however this clarity is complex. It is now known that physiological cell death, which is immunologically silent or tolerogenic, and cancer cell death, which can be immunogenic, are perceived differently by the immune system [68]. Thus, there must be mechanisms that differentiate among types of cell death [69]. Some (doxorubicin, cyclophosphamide, oxaliplatin) but not all apoptotic stimuli can induce immunogenic cell death, suggesting biochemical heterogeneity within apoptosis mechanisms. Those chemotherapeutic agents that do induce immunity depend on it for at least part of their efficacy [70,71]. There is also evidence that cells that experience stress responses and enter autophagy before undergoing apoptosis, necrosis or secondary necrosis may exhibit a more robust immunologic cell death. Induction of senescence by p53 in HCC can stimulate a robust anti-tumor response [69]. There are a number of factors that work together that determine whether cell death is immunogenic or not. These include the “history” of the cell, such as activation state or stress responses; the nature of the cell death stimulus; the cell death pathway and the availability of competent immune cells to carry out the response [69]. It appears that the pre-apoptotic exposure to calreticulin and the late apoptotic or secondary necrotic secretion of high mobility group

Figure 5: NsPEF treatment destroys HCC tumors and induces infiltration of immune cells. – N1-S1-Luc HCC tumors were initiated as described in the legend to Figure 1 and treated as described in the legend to Figure 2. Then, 14 days after treatment rats were humanely euthanized and liver tissue was taken from normal liver removed from a distant untreated lobe, from sham-treated HCC tumor and from HCC tumor treated with nsPEFs. Tissues were washed in PBS, fixed in 10% Neutral Buffered Formalin (NBF), followed by paraffin embedded, sectioning and H&E staining. Images were visualized using a Nikon Eclipse 50i microscope (Nikon, Tokyo, Japan) equipped with a 100X/0.25 numerical aperture, and acquired using a Go-5 camera (QImaging, Surrey, Canada) and QCapture Pro 6.0 software.
these agents would be used in combination with nsPEFs, their doses can be significantly reduced into non-toxic ranges.

Future directions for treatment of cancer with nsPEFs

Nearly all studies with nsPEFs have been conducted in vitro with cells in culture or in vivo as preclinical investigations in mice and rats. In essentially all of these studies, which only a limited number are discussed here, nsPEF ablation has been highly effective against all tumor cells and tissues tested. The in vivo studies reviewed here suggest that clinical trials could most easily begin with skin cancers such as squamous cell carcinoma and/or basal cell carcinoma. This is supported by one example of an nsPEF-treated basal human cell carcinoma from a single patient who had a complete pathologic response and the tumor was eliminated [75]. In fact, one human clinical trial treating basal cell carcinoma has been completed, but not yet published [76]. Of course, funding for these trials are difficult to secure and this is presently an issue with such low funding levels and financiers showing caution with investments. The other viable cancer for nsPEF ablation is cancer in internal organs such as HCC or pancreatic tumors. Before these studies begin, catheter electrodes must be developed for laparoscopy approaches which would avoid invasive surgeries. Finally, confirming and defining molecular mechanisms for presumed nsPEF-associated host immune responses will make clinical trials more attractive for physicians and patients and appealing to investors.

Acknowledgements

The authors would like to thank Dr. Jürgen Kolb, Dr. Shu Xiao and Dr. Yeong-Jer Chen for providing engineering support for these studies. We also thank Drs. Wendy Ford and Wei Ren for their help with various aspects of these studies. The authors also appreciate the technical support from Ms. Nova Sain and K. Tyler Harlow. We are also thankful for financial support from Mr. Frank Reddy. These studies also received support in part from an AFOSR/DOD MURI grant on sub cellular responses to narrowband and wideband radio frequency radiation, administered through Old Dominion University and grants from Ethicon Endo Surgery and the Virginia Center for Innovative Technology and the Commonwealth Research Commercialization Fund. The work focuses on studies from the Frank Reddy Research Center for Bioelectronics, at Old Dominion University. We apologize to the many authors in this area, who have done excellent work to advance this field, but were not referenced in this brief, focused review.

References

5. Gods and Mythology of ancient Egypt.

42. Unpublished clinical trials.
76. Development of a nanosecond pulsed electric field system to treat skin cancer ClinicalTrials.gov NCT01463709.